📊

Executive Summary

Approved once-daily TransCon PTH prodrug (palopegteriparatide) for hypoparathyroidism in adults, providing physiological PTH levels around the clock

Palopegteriparatide_YORVIPATH_TransCon_PTH

· Prodrug using TransCon technology

Approved

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy